Silodosin (KMD-3213, KAD 3213, Urief, Rapaflo, Silodyx)is an alfa1A-adrenoceptor antagonist with high uroselectivity for treatment of benigh prostatic hypertrophy. Silodosin causes practically no orthostatic hypotension (in contrast to other alfa1A blockers). Since Silodosin is a highly selective inhibitor of the alfa1A adrenergic receptor, it causes practically no orthostatic hypotension (in contrast to other alfa1A blockers).
KMD-3213, a novel α1A-adrenoceptor antagonist, potently inhibits the functional α1-adrenoceptor in human prostate.
KMD-3213, a uroselective and long-acting α1a-adrenoceptor antagonist, tested in a novel rat model.
Pharmacophore identification of α1A-adrenoceptor antagonists.
Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia.
Silodosin is effective for treatment of LUTS in men with BPH: a systematic review.
 N.Moriyamaa, et al, Eur. J. Pharmacol., 1997, 331(1), pp 39-42.
 K.Akiyama, et al, J. Pharmacol. Exp. Ther., 1999, 291(1), pp 81-91.